Search hospitals > California > Santa Monica
Providence Saint John's Health Center
Claim this profileSanta Monica, California 90404
Conducts research for Melanoma
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Tumors
Conducts research for Solid Tumors
38 reported clinical trials
8 medical researchers
Summary
Providence Saint John's Health Center is a medical facility located in Santa Monica, California. This center is recognized for care of Melanoma, Breast Cancer, Cancer, Tumors, Solid Tumors and other specialties. Providence Saint John's Health Center is involved with conducting 38 clinical trials across 80 conditions. There are 8 research doctors associated with this hospital, such as Santosh Kesari, MD, Naveed Wagle, MD, Orrin Troum, MD, and Parvin Peddi, MD.Area of expertise
1Melanoma
Stage IV
Stage III
BRAF positive
2Breast Cancer
Stage IV
Stage III
HER2 negative
Top PIs
Santosh Kesari, MDProvidence Saint John's Health Center3 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
11 reported clinical trials
16 drugs studied
Naveed Wagle, MDProvidence Saint John's Health Center3 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
7 reported clinical trials
8 drugs studied
Orrin Troum, MDProvidence St. John's Health Center1 year of reported clinical research
Studies Gout
Studies Rheumatoid Arthritis
6 reported clinical trials
6 drugs studied
Parvin Peddi, MDSaint John's Cancer Institute2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
5 reported clinical trials
14 drugs studied
Clinical Trials running at Providence Saint John's Health Center
Solid Tumors
Breast Cancer
Tumors
Squamous Cell Carcinoma
Ovarian Cancer
Melanoma
Prostate Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Pembrolizumab
for Advanced Cancers
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Recruiting2 awards Phase 34 criteria
MDNA11 + Pembrolizumab
for Cancer
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Recruiting1 award Phase 1 & 2
AdAPT-001
for Cancer
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Recruiting1 award Phase 217 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Providence Saint John's Health Center?
Providence Saint John's Health Center is a medical facility located in Santa Monica, California. This center is recognized for care of Melanoma, Breast Cancer, Cancer, Tumors, Solid Tumors and other specialties. Providence Saint John's Health Center is involved with conducting 38 clinical trials across 80 conditions. There are 8 research doctors associated with this hospital, such as Santosh Kesari, MD, Naveed Wagle, MD, Orrin Troum, MD, and Parvin Peddi, MD.